FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

ペプチドライブラリー

DSIP

Delta Sleep Inducing Peptide / Delta Sleep-Inducing Peptide

Cognitive & Neuro

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits during electrically induced slow-wave sleep by Swiss researchers Schoenenberger and Monnier in 1977. Despite its name, DSIP does not directly induce sleep but rather modulates sleep architecture, normalizes disturbed sleep-wake cycles, and influences stress adaptation, endocrine regulation, and pain perception. It is one of the earliest neuropeptides discovered and remains enigmatic due to its multiple peripheral and central effects that extend far beyond sleep regulation.

作用機序

Nonapeptide that modulates sleep architecture by increasing delta wave activity during slow-wave sleep. Acts through multiple mechanisms including GABA modulation, serotonergic signaling, and suppression of corticotropin-releasing hormone. Does not induce sedation but improves sleep quality.

研究プロトコル

研究目的のみで使用。医療アドバイスではありません。

Research protocols use 100-300mcg via subcutaneous or intramuscular injection 30-60 minutes before bedtime. Some protocols use 5-day cycles with 2-day breaks. Not recommended for continuous daily use.

研究ノート

Clinical Research Status

DSIP has been investigated in numerous clinical studies throughout the 1980s and 1990s, primarily in European research institutions, for insomnia, narcolepsy, chronic pain, opioid/alcohol withdrawal, and stress-related disorders. Despite promising results in several open-label and small controlled trials, no large Phase III trial has been conducted and DSIP holds no regulatory approval in any country. Research activity declined in the 2000s partly due to the peptide's instability and complex pharmacology that defied simple receptor-based drug development models. Interest has revived in recent years within the peptide therapy and biohacking communities.

Key Published Findings

A 1986 European Journal of Clinical Pharmacology study showed DSIP improved sleep onset latency and sleep efficiency in chronic insomniacs without morning hangover effects seen with benzodiazepines. Research demonstrated DSIP normalizes disrupted circadian cortisol patterns and reduces ACTH/cortisol responses to stress in both human and animal models. Clinical studies in opioid-dependent patients showed DSIP significantly reduced withdrawal symptoms and craving during detoxification. DSIP has been shown to modulate LH and GH secretion, lower blood pressure in hypertensive patients, and produce analgesic effects through met-enkephalin pathway modulation.

Safety Profile

Clinical studies consistently report DSIP is well-tolerated with no significant adverse effects at therapeutic doses (25-30 nmol/kg IV or 100 mcg SC). No tolerance, dependence, or withdrawal has been observed even with repeated administration over weeks. Unlike benzodiazepines and Z-drugs, DSIP does not impair cognitive function, suppress REM sleep, or produce respiratory depression. The primary practical concern is the peptide's instability in solution and susceptibility to enzymatic degradation, which affects dosing consistency rather than safety.

Drug Interactions & Contraindications

DSIP may potentiate the effects of other sedating compounds (benzodiazepines, opioids, antihistamines) through its modulatory effects on sleep architecture and endorphin systems. Its cortisol-modulating properties suggest caution in patients on corticosteroid therapy or with adrenal insufficiency. Patients on antihypertensive medications should monitor blood pressure as DSIP has demonstrated mild hypotensive effects in clinical studies. No absolute contraindications have been established, though use in pregnancy and severe hepatic/renal impairment is not recommended due to insufficient data.

Comparison to Related Compounds

Unlike benzodiazepines or Z-drugs (zolpidem, zopiclone), DSIP does not force sleep onset but rather normalizes the circadian regulation of sleep-wake cycles, improving natural sleep architecture. Compared to melatonin, DSIP has broader physiological effects beyond circadian rhythm signaling, including stress adaptation, pain modulation, and endocrine regulation. Relative to orexin receptor antagonists (suvorexant), DSIP represents a modulatory peptide approach rather than direct receptor blockade. Its multi-system effects distinguish it from all conventional sleep aids, suggesting it functions more as a homeostatic regulator than a targeted sedative-hypnotic.

Community Observations

Users typically dose DSIP at 100-300 mcg subcutaneously, administered 1-2 hours before desired sleep onset, often reporting improved sleep quality within 2-3 nights. The subjective experience is described as more restorative sleep with vivid dreams rather than sedation or forced drowsiness. Many users report best results with courses of 10-14 days rather than continuous use, noting that sleep improvements often persist after discontinuation. DSIP is frequently combined with other sleep-supporting peptides (Epithalon, GHRH analogs) and is popular among shift workers and those with travel-induced circadian disruption.

半減期

~15-25 minutes

再構成

Bacteriostatic water (BAC)

保存

乾燥粉末

Refrigerate 2-8C up to 12 months.

再溶解

Refrigerate 2-8C. Use within 14 days.

米国法的状況

Research chemical (not FDA-approved)

また知られる名前

Delta Sleep Inducing PeptideDelta Sleep-Inducing Peptide

よくある質問

DSIPとは何ですか?

DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated from the cerebral venous blood of rabbits during electrically induced slow-wave sleep by Swiss researchers Schoenenberger and Monnier in 1977. Despite its name, DSIP does not directly induce sleep but rather modulates sleep architecture, normalizes disturbed sleep-wake cycles, and influences stress adaptation, endocrine regulation, and pain perception. It is one of the earliest neuropeptides discovered and remains enigmatic due to its multiple peripheral and central effects that extend far beyond sleep regulation.

DSIPはどのように作用しますか?

Nonapeptide that modulates sleep architecture by increasing delta wave activity during slow-wave sleep. Acts through multiple mechanisms including GABA modulation, serotonergic signaling, and suppression of corticotropin-releasing hormone. Does not induce sedation but improves sleep quality.

DSIPの米国での規制状況は?

Research chemical (not FDA-approved)

DSIPの半減期は?

~15-25 minutes

DSIPの別名は?

Delta Sleep Inducing Peptide, Delta Sleep-Inducing Peptide

ペプチドコンタクトは、研究目的のみのための要約情報を提供しています。私たちはベンダーの文書をホスト、配布、または推奨していません。すべての分析証明書、GMP認定証明書、およびベンダーコミュニケーションは、購入者によって直接要求され、確認される必要があります。このプラットフォーム上の何らかの情報は法的、医学的、または専門的なアドバイスを構成していません。ユーザーは、適切な法律、州法、および連邦法に準拠するためにベンダー資格を検証し、購入前に遵守することに全責任を持つ必要があります。このプラットフォームを使用することで、完全な個人的責任を承認することになります。

完全な免責事項を読む